HB2198
Systemic Lupus Erythematosus (SLE) and Lupus Nephritis
Phase 1Active
Key Facts
Indication
Systemic Lupus Erythematosus (SLE) and Lupus Nephritis
Phase
Phase 1
Status
Active
Company
About Hinge Bio
Hinge Bio is a clinical-stage biotech advancing a novel antibody platform, GEM-DIMER™, aimed at overcoming limitations of current therapies in autoimmunity and oncology. Its lead asset, HB2198, has entered clinical development for systemic lupus erythematosus (SLE) and lupus nephritis following an FDA IND clearance in 2025. The company is led by an experienced team with a strong track record in drug development and has secured a key partnership with Kyorin Pharmaceutical for the Japanese market. Hinge Bio represents a promising player in the development of multifunctional biologics.
View full company profile